Eli Lilly's Foundayo Shows Weight Loss Efficacy in Menopausal Women

Eli Lilly and Company (NYSE:LLY) announced positive results for its oral GLP-1 medication, Foundayo (orforglipron), in promoting weight loss for women across all stages of menopause. The findings come from post-hoc analyses of the ATTAIN-1 and ATTAIN-2 clinical trials, presented at the American Diabetes Association (ADA) annual meeting.

The Product

Foundayo is an oral, once-daily GLP-1 receptor agonist designed for weight loss. The analyses showed significant efficacy in reducing body weight among postmenopausal women, a group that often struggles with weight management.

Pricing and Availability

Eli Lilly has not yet disclosed pricing or a commercial launch timeline for Foundayo. The drug remains under development and has not received FDA approval.

Competition

Foundayo competes with other GLP-1 drugs such as Novo Nordisk's (NVO) Wegovy and Eli Lilly's own Mounjaro. Its oral formulation could provide a competitive advantage over injectable alternatives.

Potential Impact on the Company

If approved, Foundayo could expand Eli Lilly's weight loss market to include menopausal women, a large underserved demographic. This could boost the company's revenue and strengthen its position in the growing obesity market.